CBS9106

Leading our preclinical pipeline is CBS9106, an orally-active synthetic small molecule of molecular mass 420. This compound was identified and optimized through a modified version of our proprietary phenotype screening platform. We have completed in vitro studies of CBS9106, demonstrating its cancer cell-specific cytotoxicity. Additional experiments have shown that CBS9106 does not inhibit most known kinases, and that the compound also shows promising activity in multiple xenograft models. The mechanism of action is known to include inhibition and destabilization of an undisclosed target, while stabilizing p53 and inducing apoptosis.

We believe that CBS9106 is a first-in-class compound, with no other products either on the market or in active clinical development that target the same molecule. Preclinical toxicology studies are currently ongoing, with first-in-human studies slated for 2H2011.

To read more about CBS9106:

• [Related News Release - PDF] CanBas' Phase II Anti-Cancer Drug CBP501 Mechanisms Include Calmodulin Binding; CBS9106 Inhibits CRM1 [April 5, 2011].
• 1. Keiichi Sakakibara, Naoya Saito, Takuji Sato, Atsushi Suzuki, Yoko Hasegawa, Jonathan M. Friedman, Masashi Suganuma, Donald W. Kufe, Daniel D. VanHoff, Tadahiko Iwami, and Takumi Kawabe: CBS9106 is a novel low toxic reversible oral CRM1 inhibitor with CRM1 degrading activity. AACR Meeting, Abstract #658, Apr 2011.
• 2. Ikeda H, Hideshima T, Perrone G, Okawa Y, Raje N, Kawabe T, Sakakibara K, Saito N, Richardson P, and Anderson K: Specific P53 stabilizer CBS9106 induces cytotoxicity in multiple myeloma (MM). J Clin Oncol 27:15s, 2009 (suppl; abstr 8601)
• 3. Sakakibara K, Saito N, Sato T, Suzuki A,Suganuma M, and Kawabe T: Abstract #1824: A novel anti-cancer compound CBS9106 activates p53 and induces apoptosis in acute lymphoblastic leukemia and multiple myeloma cells. AACR Meeting Abstracts, Apr 2009; 2009: 1824.